{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:04:06Z","timestamp":1791396246994,"version":"4.3.3"},"publisher-location":"Cham","reference-count":131,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030402037","type":"print"},{"value":"9783030402044","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-40204-4_10","type":"book-chapter","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T13:04:00Z","timestamp":1586955840000},"page":"147-162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer"],"prefix":"10.1007","author":[{"given":"Swetha","family":"Kambhampati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun P.","family":"Wiita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"e08153","DOI":"10.7554\/eLife.08153","volume":"4","author":"D Acosta-Alvear","year":"2015","unstructured":"Acosta-Alvear D et al (2015) Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits. elife 4:e08153","journal-title":"elife"},{"issue":"1","key":"10_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1634\/theoncologist.7-1-9","volume":"7","author":"J Adams","year":"2002","unstructured":"Adams J (2002) Development of the proteasome inhibitor PS-341. Oncologist 7(1):9\u201316","journal-title":"Oncologist"},{"issue":"11","key":"10_CR3","first-page":"2615","volume":"59","author":"J Adams","year":"1999","unstructured":"Adams J et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59(11):2615\u20132622","journal-title":"Cancer Res"},{"issue":"6220","key":"10_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1126\/science.1261197","volume":"347","author":"S Asano","year":"2015","unstructured":"Asano S et al (2015) Proteasomes. A molecular census of 26S proteasomes in intact neurons. Science 347(6220):439\u2013442","journal-title":"Science"},{"issue":"2","key":"10_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41375-018-0216-8","volume":"33","author":"S Barrio","year":"2019","unstructured":"Barrio S et al (2019) Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia 33(2):447\u2013456","journal-title":"Leukemia"},{"key":"10_CR6","doi-asserted-by":"crossref","unstructured":"Barwick BG, Gupta VA, Vertino PM, Boise LH (2019) Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Front Immunol. ePub ahead of print","DOI":"10.3389\/fimmu.2019.01121"},{"issue":"3","key":"10_CR7","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jmb.2008.12.081","volume":"386","author":"JM Baugh","year":"2009","unstructured":"Baugh JM, Viktorova EG, Pilipenko EV (2009) Proteasomes can degrade a significant proportion of cellular proteins independent of ubiquitination. J Mol Biol 386(3):814\u2013827","journal-title":"J Mol Biol"},{"issue":"7718","key":"10_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","volume":"560","author":"U Ben-David","year":"2018","unstructured":"Ben-David U et al (2018) Genetic and transcriptional evolution alters cancer cell line drug response. Nature 560(7718):325\u2013330","journal-title":"Nature"},{"issue":"2","key":"10_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/leu.2017.212","volume":"32","author":"A Besse","year":"2018","unstructured":"Besse A et al (2018) Carfilzomib resistance due to ABCB1\/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia 32(2):391\u2013401","journal-title":"Leukemia"},{"issue":"3","key":"10_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","volume":"26","author":"A Besse","year":"2019","unstructured":"Besse A et al (2019) Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors. Cell Chem Biol 26(3):340\u2013351. e343","journal-title":"Cell Chem Biol"},{"issue":"20","key":"10_CR11","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","volume":"125","author":"G Bianchi","year":"2015","unstructured":"Bianchi G, Munshi NC (2015) Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 125(20):3049\u20133058","journal-title":"Blood"},{"issue":"13","key":"10_CR12","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","volume":"113","author":"G Bianchi","year":"2009","unstructured":"Bianchi G et al (2009) The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113(13):3040\u20133049","journal-title":"Blood"},{"issue":"3","key":"10_CR13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1084\/jem.179.3.901","volume":"179","author":"B Boes","year":"1994","unstructured":"Boes B et al (1994) Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med 179(3):901\u2013909","journal-title":"J Exp Med"},{"issue":"4","key":"10_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ccr.2007.02.015","volume":"11","author":"DR Carrasco","year":"2007","unstructured":"Carrasco DR et al (2007) The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11(4):349\u2013360","journal-title":"Cancer Cell"},{"issue":"5","key":"10_CR15","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1189\/jlb.1011497","volume":"92","author":"S Cenci","year":"2012","unstructured":"Cenci S et al (2012) Pivotal advance: protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J Leukoc Biol 92(5):921\u2013931","journal-title":"J Leukoc Biol"},{"issue":"9","key":"10_CR16","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.3390\/ijms18091978","volume":"18","author":"S Chatterjee","year":"2017","unstructured":"Chatterjee S, Burns TF (2017) Targeting heat shock proteins in Cancer: a promising therapeutic approach. Int J Mol Sci 18(9):1978","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","volume":"8","author":"D Chauhan","year":"2005","unstructured":"Chauhan D et al (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8(5):407\u2013419","journal-title":"Cancer Cell"},{"issue":"16","key":"10_CR18","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","volume":"17","author":"D Chauhan","year":"2011","unstructured":"Chauhan D et al (2011) In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17(16):5311\u20135321","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","volume":"22","author":"D Chauhan","year":"2012","unstructured":"Chauhan D et al (2012) A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22(3):345\u2013358","journal-title":"Cancer Cell"},{"issue":"8","key":"10_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.trecan.2018.05.005","volume":"4","author":"P Choudhry","year":"2018","unstructured":"Choudhry P, Galligan D, Wiita AP (2018) Seeking convergence and cure with new myeloma therapies. Trends Cancer 4(8):567\u2013582","journal-title":"Trends Cancer"},{"issue":"8","key":"10_CR21","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1021\/acscentsci.7b00252","volume":"3","author":"PM Cromm","year":"2017","unstructured":"Cromm PM, Crews CM (2017) The proteasome in modern drug discovery: second life of a highly valuable drug target. ACS Cent Sci 3(8):830\u2013838","journal-title":"ACS Cent Sci"},{"issue":"15","key":"10_CR22","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.2174\/138161211796197124","volume":"17","author":"B Cvek","year":"2011","unstructured":"Cvek B, Dvorak Z (2011) The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib. Curr Pharm Des 17(15):1483\u20131499","journal-title":"Curr Pharm Des"},{"issue":"13","key":"10_CR23","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1002\/anie.201509092","volume":"55","author":"G de Bruin","year":"2016","unstructured":"de Bruin G et al (2016) A set of activity-based probes to visualize human (Immuno)proteasome activities. Angew Chem 55(13):4199\u20134203","journal-title":"Angew Chem"},{"issue":"13","key":"10_CR24","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","volume":"67","author":"SD Demo","year":"2007","unstructured":"Demo SD et al (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67(13):6383\u20136391","journal-title":"Cancer Res"},{"issue":"37","key":"10_CR25","doi-asserted-by":"publisher","first-page":"60698","DOI":"10.18632\/oncotarget.10849","volume":"7","author":"L Di Marzo","year":"2016","unstructured":"Di Marzo L et al (2016) Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget 7(37):60698\u201360711","journal-title":"Oncotarget"},{"issue":"1","key":"10_CR26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3324\/haematol.2014.112037","volume":"100","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA et al (2015) Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica 100(1):100\u2013106","journal-title":"Haematologica"},{"issue":"1","key":"10_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA et al (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27\u201338","journal-title":"Lancet Oncol"},{"issue":"10","key":"10_CR28","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA et al (2017a) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18(10):1327\u20131337","journal-title":"Lancet Oncol"},{"issue":"7","key":"10_CR29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/bloodadvances.2016003269","volume":"1","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA et al (2017b) Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv 1(7):449\u2013454","journal-title":"Blood Adv"},{"issue":"7737","key":"10_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41586-018-0736-4","volume":"565","author":"Y Dong","year":"2019","unstructured":"Dong Y et al (2019) Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome. Nature 565(7737):49\u201355","journal-title":"Nature"},{"issue":"8","key":"10_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0145-2126(99)00195-2","volume":"24","author":"HG Drexler","year":"2000","unstructured":"Drexler HG, Matsuo Y (2000) Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk Res 24(8):681\u2013703","journal-title":"Leuk Res"},{"issue":"10068","key":"10_CR32","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie BG et al (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389(10068):519\u2013527","journal-title":"Lancet"},{"issue":"35","key":"10_CR33","doi-asserted-by":"publisher","first-page":"56726","DOI":"10.18632\/oncotarget.11059","volume":"7","author":"D Dytfeld","year":"2016","unstructured":"Dytfeld D et al (2016) Comparative proteomic profiling of refractory\/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. Oncotarget 7(35):56726\u201356736","journal-title":"Oncotarget"},{"issue":"1","key":"10_CR34","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bbamcr.2013.05.008","volume":"1843","author":"J Erales","year":"2014","unstructured":"Erales J, Coffino P (2014) Ubiquitin-independent proteasomal degradation. Biochim Biophys Acta 1843(1):216\u2013221","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"10_CR35","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2174\/0929867323666160318173706","volume":"23","author":"R Ettari","year":"2016","unstructured":"Ettari R, Previti S, Bitto A, Grasso S, Zappala M (2016) Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases. Curr Med Chem 23(12):1217\u20131238","journal-title":"Curr Med Chem"},{"issue":"9","key":"10_CR36","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","volume":"27","author":"DA Fennell","year":"2008","unstructured":"Fennell DA, Chacko A, Mutti L (2008) BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 27(9):1189\u20131197","journal-title":"Oncogene"},{"key":"10_CR37","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1182\/blood-2018-99-117401","volume":"132","author":"I Ferguson","year":"2018","unstructured":"Ferguson I et al (2018) Novel allosteric inhibitors of heat shock protein 70 as agents to probe protein homeostasis and overcome proteasome inhibitor resistance in multiple myeloma. Blood (ASH Abstract) 132:3212","journal-title":"Blood (ASH Abstract)"},{"issue":"30","key":"10_CR38","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI et al (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24(30):4867\u20134874","journal-title":"J Clin Oncol"},{"issue":"7624","key":"10_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nature19800","volume":"538","author":"M Franke","year":"2016","unstructured":"Franke M et al (2016) Formation of new chromatin domains determines pathogenicity of genomic duplications. Nature 538(7624):265\u2013269","journal-title":"Nature"},{"issue":"4","key":"10_CR40","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S et al (2017) The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev 36(4):561\u2013584","journal-title":"Cancer Metastasis Rev"},{"issue":"50","key":"10_CR41","doi-asserted-by":"publisher","first-page":"49047","DOI":"10.1074\/jbc.M205011200","volume":"277","author":"JN Gass","year":"2002","unstructured":"Gass JN, Gifford NM, Brewer JW (2002) Activation of an unfolded protein response during differentiation of antibody-secreting B cells. J Biol Chem 277(50):49047\u201349054","journal-title":"J Biol Chem"},{"issue":"2","key":"10_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nchembio.2528","volume":"14","author":"G Gavory","year":"2018","unstructured":"Gavory G et al (2018) Discovery and characterization of highly potent and selective allosteric USP7 inhibitors. Nat Chem Biol 14(2):118\u2013125","journal-title":"Nat Chem Biol"},{"issue":"4","key":"10_CR43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1083\/jcb.201210077","volume":"199","author":"AL Goldberg","year":"2012","unstructured":"Goldberg AL (2012) Development of proteasome inhibitors as research tools and cancer drugs. J Cell Biol 199(4):583\u2013588","journal-title":"J Cell Biol"},{"issue":"7620","key":"10_CR44","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature19947","volume":"537","author":"JW Harper","year":"2016","unstructured":"Harper JW, Bennett EJ (2016) Proteome complexity and the forces that drive proteome imbalance. Nature 537(7620):328\u2013338","journal-title":"Nature"},{"key":"10_CR45","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A Hershko","year":"1998","unstructured":"Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425\u2013479","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"10_CR46","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.molcel.2017.06.017","volume":"69","author":"C Hetz","year":"2018","unstructured":"Hetz C, Papa FR (2018) The unfolded protein response and cell fate control. Mol Cell 69(2):169\u2013181","journal-title":"Mol Cell"},{"issue":"7","key":"10_CR47","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61(7):3071\u20133076","journal-title":"Cancer Res"},{"issue":"19","key":"10_CR48","doi-asserted-by":"publisher","first-page":"16639","DOI":"10.1074\/jbc.M200360200","volume":"277","author":"T Hideshima","year":"2002","unstructured":"Hideshima T et al (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277(19):16639\u201316647","journal-title":"J Biol Chem"},{"issue":"11","key":"10_CR49","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","volume":"10","author":"T Hideshima","year":"2011","unstructured":"Hideshima T, Richardson PG, Anderson KC (2011) Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 10(11):2034\u20132042","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10_CR50","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.2217\/fon.14.30","volume":"10","author":"Z Huang","year":"2014","unstructured":"Huang Z et al (2014) Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. Future Oncol 10(10):1795\u20131807","journal-title":"Future Oncol"},{"issue":"9","key":"10_CR51","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nsmb.3273","volume":"23","author":"X Huang","year":"2016","unstructured":"Huang X, Luan B, Wu J, Shi Y (2016) An atomic structure of the human 26S proteasome. Nat Struct Mol Biol 23(9):778\u2013785","journal-title":"Nat Struct Mol Biol"},{"key":"10_CR52","doi-asserted-by":"crossref","unstructured":"Huang HH et al (2020) Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. Nat Commun. In press","DOI":"10.1038\/s41467-020-15521-4"},{"issue":"14","key":"10_CR53","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1111\/febs.13598","volume":"283","author":"R Iurlaro","year":"2016","unstructured":"Iurlaro R, Munoz-Pinedo C (2016) Cell death induced by endoplasmic reticulum stress. FEBS J 283(14):2640\u20132652","journal-title":"FEBS J"},{"issue":"2","key":"10_CR54","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","volume":"127","author":"S Jagannath","year":"2004","unstructured":"Jagannath S et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127(2):165\u2013172","journal-title":"Br J Haematol"},{"issue":"2","key":"10_CR55","first-page":"153","volume":"1786","author":"I Jariel-Encontre","year":"2008","unstructured":"Jariel-Encontre I, Bossis G, Piechaczyk M (2008) Ubiquitin-independent degradation of proteins by the proteasome. Biochim Biophys Acta 1786(2):153\u2013177","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10_CR56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.tcb.2014.09.001","volume":"25","author":"CM Kenific","year":"2015","unstructured":"Kenific CM, Debnath J (2015) Cellular and metabolic functions for autophagy in cancer cells. Trends Cell Biol 25(1):37\u201345","journal-title":"Trends Cell Biol"},{"key":"10_CR57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-biophys-083012-130417","volume":"42","author":"E Kish-Trier","year":"2013","unstructured":"Kish-Trier E, Hill CP (2013) Structural biology of the proteasome. Annu Rev Biophys 42:29\u201349","journal-title":"Annu Rev Biophys"},{"issue":"6","key":"10_CR58","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.tcb.2013.12.003","volume":"24","author":"G Kleiger","year":"2014","unstructured":"Kleiger G, Mayor T (2014) Perilous journey: a tour of the ubiquitin-proteasome system. Trends Cell Biol 24(6):352\u2013359","journal-title":"Trends Cell Biol"},{"issue":"10","key":"10_CR59","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3324\/haematol.2014.109421","volume":"100","author":"M Kraus","year":"2015","unstructured":"Kraus M et al (2015) The novel beta2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica 100(10):1350\u20131360","journal-title":"Haematologica"},{"issue":"9","key":"10_CR60","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","volume":"110","author":"DJ Kuhn","year":"2007","unstructured":"Kuhn DJ et al (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110(9):3281\u20133290","journal-title":"Blood"},{"issue":"5","key":"10_CR61","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","volume":"70","author":"E Kupperman","year":"2010","unstructured":"Kupperman E et al (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70(5):1970\u20131980","journal-title":"Cancer Res"},{"issue":"7384","key":"10_CR62","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature10774","volume":"482","author":"GC Lander","year":"2012","unstructured":"Lander GC et al (2012) Complete subunit architecture of the proteasome regulatory particle. Nature 482(7384):186\u2013191","journal-title":"Nature"},{"issue":"2","key":"10_CR63","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274\u2013293","journal-title":"Cell"},{"issue":"5","key":"10_CR64","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1073\/pnas.1120559109","volume":"109","author":"K Lasker","year":"2012","unstructured":"Lasker K et al (2012) Molecular architecture of the 26S proteasome holocomplex determined by an integrative approach. Proc Natl Acad Sci U S A 109(5):1380\u20131387","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10_CR65","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1158\/1535-7163.MCT-17-0233","volume":"16","author":"R Le Moigne","year":"2017","unstructured":"Le Moigne R et al (2017) The p97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of Multiple Myeloma. Mol Cancer Ther 16(11):2375\u20132386","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10_CR66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clml.2018.08.016","volume":"19","author":"X Leleu","year":"2019","unstructured":"Leleu X et al (2019) Role of proteasome inhibitors in relapsed and\/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 19(1):9\u201322","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10_CR67","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","volume":"24","author":"C Leung-Hagesteijn","year":"2013","unstructured":"Leung-Hagesteijn C et al (2013) Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 24(3):289\u2013304","journal-title":"Cancer Cell"},{"issue":"9","key":"10_CR68","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrc.2017.53","volume":"17","author":"JMM Levy","year":"2017","unstructured":"Levy JMM, Towers CG, Thorburn A (2017) Targeting autophagy in cancer. Nat Rev Cancer 17(9):528\u2013542","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10_CR69","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1158\/1535-7163.MCT-07-2444","volume":"7","author":"C Li","year":"2008","unstructured":"Li C, Li R, Grandis JR, Johnson DE (2008) Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther 7(6):1647\u20131655","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10_CR70","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1158\/1535-7163.MCT-14-0650","volume":"14","author":"X Li","year":"2015","unstructured":"Li X et al (2015) Validation of the Hsp70-Bag3 protein-protein interaction as a potential therapeutic target in cancer. Mol Cancer Ther 14(3):642\u2013648","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10_CR71","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3324\/haematol.2011.043331","volume":"97","author":"SC Ling","year":"2012","unstructured":"Ling SC et al (2012) Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica 97(1):64\u201372","journal-title":"Haematologica"},{"key":"10_CR72","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fcell.2019.00060","volume":"7","author":"T Liu","year":"2019","unstructured":"Liu T, Zhou L, Li D, Andl T, Zhang Y (2019a) Cancer-associated fibroblasts build and secure the tumor microenvironment. Front Cell Dev Biol 7:60","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"10_CR73","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41587-019-0037-y","volume":"37","author":"Y Liu","year":"2019","unstructured":"Liu Y et al (2019b) Multi-omic measurements of heterogeneity in HeLa cells across laboratories. Nat Biotechnol 37(3):314\u2013322","journal-title":"Nat Biotechnol"},{"issue":"9","key":"10_CR74","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1158\/1078-0432.CCR-13-1610","volume":"20","author":"CM Lovly","year":"2014","unstructured":"Lovly CM, Shaw AT (2014) Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res 20(9):2249\u20132256","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10_CR75","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/MOH.0000000000000259","volume":"23","author":"S Manier","year":"2016","unstructured":"Manier S, Kawano Y, Bianchi G, Roccaro AM, Ghobrial IM (2016) Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma. Curr Opin Hematol 23(4):426\u2013433","journal-title":"Curr Opin Hematol"},{"key":"10_CR76","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.semcancer.2016.08.005","volume":"39","author":"GM Matthews","year":"2016","unstructured":"Matthews GM et al (2016) NF-kappaB dysregulation in multiple myeloma. Semin Cancer Biol 39:68\u201376","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"10_CR77","doi-asserted-by":"publisher","first-page":"e581","DOI":"10.1038\/bcj.2017.56","volume":"7","author":"AK Mitra","year":"2017","unstructured":"Mitra AK et al (2017) A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. Blood Cancer J 7(6):e581","journal-title":"Blood Cancer J"},{"issue":"22","key":"10_CR78","doi-asserted-by":"publisher","first-page":"14374","DOI":"10.1073\/pnas.202445099","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades N et al (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99(22):14374\u201314379","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10_CR79","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","volume":"147","author":"N Mizushima","year":"2011","unstructured":"Mizushima N, Komatsu M (2011) Autophagy: renovation of cells and tissues. Cell 147(4):728\u2013741","journal-title":"Cell"},{"key":"10_CR80","doi-asserted-by":"crossref","unstructured":"Moore PC et al (2019) Parallel signaling through IRE1\u03b1 and PERK regulates pancreatic neuroendocrine tumor growth and survival. Cancer Res 79(24):6190\u20136203","DOI":"10.1158\/0008-5472.CAN-19-1116"},{"issue":"8","key":"10_CR81","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","volume":"109","author":"G Mulligan","year":"2007","unstructured":"Mulligan G et al (2007) Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 109(8):3177\u20133188","journal-title":"Blood"},{"issue":"21","key":"10_CR82","doi-asserted-by":"publisher","first-page":"12504","DOI":"10.1073\/pnas.95.21.12504","volume":"95","author":"AK Nussbaum","year":"1998","unstructured":"Nussbaum AK et al (1998) Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci U S A 95(21):12504\u201312509","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"10_CR83","doi-asserted-by":"publisher","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","volume":"15","author":"OA O\u2019Connor","year":"2009","unstructured":"O\u2019Connor OA et al (2009) A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 15(22):7085\u20137091","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10_CR84","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA et al (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107(12):4907\u20134916","journal-title":"Blood"},{"issue":"6","key":"10_CR85","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","volume":"112","author":"R Oerlemans","year":"2008","unstructured":"Oerlemans R et al (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112(6):2489\u20132499","journal-title":"Blood"},{"issue":"15","key":"10_CR86","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1182\/blood-2015-08-665679","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva B et al (2016) Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood 127(15):1896\u20131906","journal-title":"Blood"},{"issue":"5","key":"10_CR87","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","volume":"78","author":"VJ Palombella","year":"1994","unstructured":"Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78(5):773\u2013785","journal-title":"Cell"},{"issue":"4","key":"10_CR88","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00280-013-2267-x","volume":"72","author":"KP Papadopoulos","year":"2013","unstructured":"Papadopoulos KP et al (2013) A phase I\/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol 72(4):861\u2013868","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10_CR89","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1006\/jmbi.1993.1646","volume":"234","author":"JM Peters","year":"1993","unstructured":"Peters JM, Cejka Z, Harris JR, Kleinschmidt JA, Baumeister W (1993) Structural features of the 26 S proteasome complex. J Mol Biol 234(4):932\u2013937","journal-title":"J Mol Biol"},{"key":"10_CR90","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/PPA.S38142","volume":"8","author":"MT Petrucci","year":"2014","unstructured":"Petrucci MT, Finsinger P, Chisini M, Gentilini F (2014) Subcutaneous bortezomib for multiple myeloma treatment: patients\u2019 benefits. Patient Prefer Adherence 8:939\u2013946","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"10_CR91","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nrm2468","volume":"9","author":"T Ravid","year":"2008","unstructured":"Ravid T, Hochstrasser M (2008) Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol 9(9):679\u2013690","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10_CR92","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tcb.2004.11.003","volume":"15","author":"M Rechsteiner","year":"2005","unstructured":"Rechsteiner M, Hill CP (2005) Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 15(1):27\u201333","journal-title":"Trends Cell Biol"},{"issue":"8","key":"10_CR93","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1182\/blood-2009-02-203398","volume":"114","author":"DE Reece","year":"2009","unstructured":"Reece DE et al (2009) Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 114(8):1489\u20131497","journal-title":"Blood"},{"issue":"26","key":"10_CR94","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609\u20132617","journal-title":"N Engl J Med"},{"issue":"24","key":"10_CR95","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487\u20132498","journal-title":"N Engl J Med"},{"issue":"2","key":"10_CR96","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00280-017-3489-0","volume":"81","author":"MSF Roeten","year":"2018","unstructured":"Roeten MSF, Cloos J, Jansen G (2018) Positioning of proteasome inhibitors in therapy of solid malignancies. Cancer Chemother Pharmacol 81(2):227\u2013243","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10_CR97","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906\u2013917","journal-title":"N Engl J Med"},{"issue":"45","key":"10_CR98","doi-asserted-by":"publisher","first-page":"46723","DOI":"10.1074\/jbc.M406537200","volume":"279","author":"T Saric","year":"2004","unstructured":"Saric T, Graef CI, Goldberg AL (2004) Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J Biol Chem 279(45):46723\u201346732","journal-title":"J Biol Chem"},{"issue":"6779","key":"10_CR99","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/35008096","volume":"404","author":"U Schubert","year":"2000","unstructured":"Schubert U et al (2000) Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404(6779):770\u2013774","journal-title":"Nature"},{"issue":"1","key":"10_CR100","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.immuni.2004.06.010","volume":"21","author":"AL Shaffer","year":"2004","unstructured":"Shaffer AL et al (2004) XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 21(1):81\u201393","journal-title":"Immunity"},{"key":"10_CR101","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000437179","volume":"42","author":"A Shanker","year":"2015","unstructured":"Shanker A, Dikov MM, Carbone DP (2015) Promise of immunotherapy in lung Cancer. Prog Tumor Res 42:95\u2013109","journal-title":"Prog Tumor Res"},{"issue":"14","key":"10_CR102","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1021\/acs.jmedchem.8b00583","volume":"61","author":"H Shao","year":"2018","unstructured":"Shao H et al (2018) Exploration of Benzothiazole Rhodacyanines as allosteric inhibitors of protein-protein interactions with heat shock protein 70 (Hsp70). J Med Chem 61(14):6163\u20136177","journal-title":"J Med Chem"},{"issue":"8","key":"10_CR103","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel DS et al (2018) Improvement in overall survival with Carfilzomib, Lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 36(8):728\u2013734","journal-title":"J Clin Oncol"},{"issue":"9","key":"10_CR104","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00018-011-0657-y","volume":"68","author":"EJ Sijts","year":"2011","unstructured":"Sijts EJ, Kloetzel PM (2011) The role of the proteasome in the generation of MHC class I ligands and immune responses. Cell Mol Life Sci 68(9):1491\u20131502","journal-title":"Cell Mol Life Sci"},{"key":"10_CR105","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-pharmtox-010814-124727","volume":"56","author":"P Sledz","year":"2016","unstructured":"Sledz P, Baumeister W (2016) Structure-driven developments of 26S proteasome inhibitors. Annu Rev Pharmacol Toxicol 56:191\u2013209","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"11","key":"10_CR106","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/leu.2016.102","volume":"30","author":"GP Soriano","year":"2016","unstructured":"Soriano GP et al (2016) Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia 30(11):2198","journal-title":"Leukemia"},{"issue":"12","key":"10_CR107","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","volume":"103","author":"A Spencer","year":"2018","unstructured":"Spencer A et al (2018a) Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica 103(12):2079\u20132087","journal-title":"Haematologica"},{"issue":"1","key":"10_CR108","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/bjh.14987","volume":"180","author":"A Spencer","year":"2018","unstructured":"Spencer A et al (2018b) A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. Br J Haematol 180(1):41\u201351","journal-title":"Br J Haematol"},{"issue":"2","key":"10_CR109","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK et al (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142\u2013152","journal-title":"N Engl J Med"},{"issue":"6","key":"10_CR110","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1158\/0008-5472.CAN-06-3254","volume":"67","author":"SJ Strauss","year":"2007","unstructured":"Strauss SJ et al (2007) The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 67(6):2783\u20132790","journal-title":"Cancer Res"},{"issue":"2","key":"10_CR111","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.molcel.2012.08.003","volume":"48","author":"A Suraweera","year":"2012","unstructured":"Suraweera A, Munch C, Hanssum A, Bertolotti A (2012) Failure of amino acid homeostasis causes cell death following proteasome inhibition. Mol Cell 48(2):242\u2013253","journal-title":"Mol Cell"},{"issue":"1","key":"10_CR112","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2183\/pjab.85.12","volume":"85","author":"K Tanaka","year":"2009","unstructured":"Tanaka K (2009) The proteasome: overview of structure and functions. Proc Jpn Acad Ser B Phys Biol Sci 85(1):12\u201336","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"5","key":"10_CR113","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","volume":"123","author":"Z Tian","year":"2014","unstructured":"Tian Z et al (2014) A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 123(5):706\u2013716","journal-title":"Blood"},{"issue":"22","key":"10_CR114","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1002\/j.1460-2075.1994.tb06878.x","volume":"13","author":"EB Traenckner","year":"1994","unstructured":"Traenckner EB, Wilk S, Baeuerle PA (1994) A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 13(22):5433\u20135441","journal-title":"EMBO J"},{"issue":"23","key":"10_CR115","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","volume":"27","author":"SP Treon","year":"2009","unstructured":"Treon SP et al (2009) Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 27(23):3830\u20133835","journal-title":"J Clin Oncol"},{"issue":"3","key":"10_CR116","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A et al (2017) Defining a Cancer dependency map. Cell 170(3):564\u2013576. e516","journal-title":"Cell"},{"key":"10_CR117","doi-asserted-by":"publisher","first-page":"e08467","DOI":"10.7554\/eLife.08467","volume":"4","author":"P Tsvetkov","year":"2015","unstructured":"Tsvetkov P et al (2015) Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome. elife 4:e08467","journal-title":"elife"},{"issue":"2","key":"10_CR118","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1073\/pnas.1619067114","volume":"114","author":"P Tsvetkov","year":"2017","unstructured":"Tsvetkov P et al (2017) Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers. Proc Natl Acad Sci U S A 114(2):382\u2013387","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10_CR119","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41419-018-0806-4","volume":"9","author":"P Tsvetkov","year":"2018","unstructured":"Tsvetkov P et al (2018) Oncogenic addiction to high 26S proteasome level. Cell Death Dis 9(7):773","journal-title":"Cell Death Dis"},{"issue":"7","key":"10_CR120","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41589-019-0291-9","volume":"15","author":"P Tsvetkov","year":"2019","unstructured":"Tsvetkov P et al (2019) Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol 15(7):681\u2013689","journal-title":"Nat Chem Biol"},{"issue":"2","key":"10_CR121","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1073\/pnas.92.2.584","volume":"92","author":"V Ustrell","year":"1995","unstructured":"Ustrell V, Pratt G, Rechsteiner M (1995) Effects of interferon gamma and major histocompatibility complex-encoded subunits on peptidase activities of human multicatalytic proteases. Proc Natl Acad Sci U S A 92(2):584\u2013588","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 10","key":"10_CR122","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1242\/jcs.03008","volume":"119","author":"A von Mikecz","year":"2006","unstructured":"von Mikecz A (2006) The nuclear ubiquitin-proteasome system. J Cell Sci 119(Pt 10):1977\u20131984","journal-title":"J Cell Sci"},{"issue":"6059","key":"10_CR123","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1126\/science.1209038","volume":"334","author":"P Walter","year":"2011","unstructured":"Walter P, Ron D (2011) The unfolded protein response: from stress pathway to homeostatic regulation. Science 334(6059):1081\u20131086","journal-title":"Science"},{"issue":"3","key":"10_CR124","doi-asserted-by":"publisher","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","volume":"4","author":"AJ Waxman","year":"2018","unstructured":"Waxman AJ et al (2018) Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol 4(3):e174519","journal-title":"JAMA Oncol"},{"issue":"2","key":"10_CR125","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.chembiol.2016.12.016","volume":"24","author":"ES Weyburne","year":"2017","unstructured":"Weyburne ES et al (2017) Inhibition of the proteasome beta2 site sensitizes triple-negative breast Cancer cells to beta5 inhibitors and suppresses Nrf1 activation. Cell Chem Biol 24(2):218\u2013230","journal-title":"Cell Chem Biol"},{"key":"10_CR126","doi-asserted-by":"publisher","first-page":"e01236","DOI":"10.7554\/eLife.01236","volume":"2","author":"AP Wiita","year":"2013","unstructured":"Wiita AP et al (2013) Global cellular response to chemotherapy-induced apoptosis. elife 2:e01236","journal-title":"elife"},{"key":"10_CR127","doi-asserted-by":"publisher","first-page":"e27364","DOI":"10.7554\/eLife.27364","volume":"6","author":"MB Winter","year":"2017","unstructured":"Winter MB et al (2017) Immunoproteasome functions explained by divergence in cleavage specificity and regulation. elife 6:e27364","journal-title":"elife"},{"issue":"7516","key":"10_CR128","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature13485","volume":"513","author":"AL Wolfe","year":"2014","unstructured":"Wolfe AL et al (2014) RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature 513(7516):65\u201370","journal-title":"Nature"},{"issue":"3","key":"10_CR129","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1006\/jsbi.1993.1050","volume":"111","author":"T Yoshimura","year":"1993","unstructured":"Yoshimura T et al (1993) Molecular characterization of the \u201c26S\u201d proteasome complex from rat liver. J Struct Biol 111(3):200\u2013211","journal-title":"J Struct Biol"},{"issue":"5","key":"10_CR130","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ccell.2016.03.026","volume":"29","author":"XD Zhang","year":"2016","unstructured":"Zhang XD et al (2016) Tight junction protein 1 modulates proteasome capacity and proteasome inhibitor sensitivity in multiple myeloma via EGFR\/JAK1\/STAT3 Signaling. Cancer Cell 29(5):639\u2013652","journal-title":"Cancer Cell"},{"issue":"52","key":"10_CR131","doi-asserted-by":"publisher","first-page":"15790","DOI":"10.1073\/pnas.1521919112","volume":"112","author":"J Zhao","year":"2015","unstructured":"Zhao J, Zhai B, Gygi SP, Goldberg AL (2015) mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy. Proc Natl Acad Sci U S A 112(52):15790\u201315797","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Advances in Experimental Medicine and Biology","HSF1 and Molecular Chaperones in Biology and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-40204-4_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T05:06:05Z","timestamp":1649826365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-40204-4_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030402037","9783030402044"],"references-count":131,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-40204-4_10","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"16 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}